The big news in the drug sector is the emergence of GLP-1 weight loss drugs, but dig deeper, and you'll find relatively cheap ...

Now, it’s worth noting Stock Advisor’s total average return is 971 % — a market-crushing outperformance compared to 196% for ...

At a Case Management Conference in the Multi District Litigation against Pfizer Inc. (NYSE:PFE), the Honorable M. Casey Rodgers set a date for the first Trial, which will take place in December 2026, ...

More than a dozen pharmas have recently struck deals with the White House to lower drug prices. Nevertheless, drugmakers ...

Only a handful of the top pharmas have signed Most Favored Nation drug pricing deals with the White House, while smaller ...

Pfizer (NYSE:PFE) has received FDA accelerated approval for its drug Braftovi in combination with other therapies as a first-line treatment for metastatic colorectal cancer, or mCRC, with a BRAF gene ...

Pfizer (PFE) stock has attracted fresh attention after recent trading left its one-month return at a 3.3% decline and its ...

Pfizer is penning a cancer discovery pact with Cartography Biosciences that could max out at $865 million biobucks. | Pfizer ...

The group will discus and vote on whether to recommend Pfizer booster shots. The Food and Drug Administration's independent advisory committee will convene in open session Friday to review the latest ...

A patient died after receiving Pfizer Inc.’s drug for hemophilia, marking another setback for the company in the treatment of blood disorders.